BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pfeffer G, Horvath R, Klopstock T, Mootha VK, Suomalainen A, Koene S, Hirano M, Zeviani M, Bindoff LA, Yu-Wai-Man P, Hanna M, Carelli V, McFarland R, Majamaa K, Turnbull DM, Smeitink J, Chinnery PF. New treatments for mitochondrial disease-no time to drop our standards. Nat Rev Neurol 2013;9:474-81. [PMID: 23817350 DOI: 10.1038/nrneurol.2013.129] [Cited by in Crossref: 120] [Cited by in F6Publishing: 103] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Parikh S, Goldstein A, Karaa A, Koenig MK, Anselm I, Brunel-Guitton C, Christodoulou J, Cohen BH, Dimmock D, Enns GM, Falk MJ, Feigenbaum A, Frye RE, Ganesh J, Griesemer D, Haas R, Horvath R, Korson M, Kruer MC, Mancuso M, McCormack S, Raboisson MJ, Reimschisel T, Salvarinova R, Saneto RP, Scaglia F, Shoffner J, Stacpoole PW, Sue CM, Tarnopolsky M, Van Karnebeek C, Wolfe LA, Cunningham ZZ, Rahman S, Chinnery PF. Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med 2017;19. [PMID: 28749475 DOI: 10.1038/gim.2017.107] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 15.2] [Reference Citation Analysis]
2 Nogueira C, Almeida LS, Nesti C, Pezzini I, Videira A, Vilarinho L, Santorelli FM. Syndromes associated with mitochondrial DNA depletion. Ital J Pediatr 2014;40:34. [PMID: 24708634 DOI: 10.1186/1824-7288-40-34] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
3 Danhauser K, Smeitink JAM, Freisinger P, Sperl W, Sabir H, Hadzik B, Mayatepek E, Morava E, Distelmaier F. Treatment options for lactic acidosis and metabolic crisis in children with mitochondrial disease. J Inherit Metab Dis 2015;38:467-75. [DOI: 10.1007/s10545-014-9796-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
4 Na JH, Lee MJ, Lee CH, Lee YM. Association Between Epilepsy and Leigh Syndrome With MT-ND3 Mutation, Particularly the m.10191T>C Point Mutation. Front Neurol 2021;12:752467. [PMID: 34956047 DOI: 10.3389/fneur.2021.752467] [Reference Citation Analysis]
5 Steele HE, Horvath R, Lyon JJ, Chinnery PF. Monitoring clinical progression with mitochondrial disease biomarkers. Brain. 2017;140:2530-2540. [PMID: 28969370 DOI: 10.1093/brain/awx168] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
6 Motori E, Atanassov I, Kochan SMV, Folz-Donahue K, Sakthivelu V, Giavalisco P, Toni N, Puyal J, Larsson NG. Neuronal metabolic rewiring promotes resilience to neurodegeneration caused by mitochondrial dysfunction. Sci Adv 2020;6:eaba8271. [PMID: 32923630 DOI: 10.1126/sciadv.aba8271] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
7 Sciorio R, Aiello R, Irollo AM. Review: Preimplantation genetic diagnosis (PGD) as a reproductive option in patients with neurodegenerative disorders. Reprod Biol 2021;21:100468. [PMID: 33321391 DOI: 10.1016/j.repbio.2020.100468] [Reference Citation Analysis]
8 Franik S, Huidekoper HH, Visser G, de Vries M, de Boer L, Hermans-Peters M, Rodenburg R, Verhaak C, Vlieger AM, Smeitink JA, Janssen MC, Wortmann SB. High prevalence of complementary and alternative medicine use in patients with genetically proven mitochondrial disorders. J Inherit Metab Dis 2015;38:477-82. [PMID: 25303853 DOI: 10.1007/s10545-014-9773-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
9 Chinnery PF. Mitochondrial disease in adults: what's old and what's new? EMBO Mol Med 2015;7:1503-12. [PMID: 26612854 DOI: 10.15252/emmm.201505079] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 13.2] [Reference Citation Analysis]
10 Yu-Wai-Man P. Harnessing the Power of Genetic Engineering for Patients With Mitochondrial Eye Diseases. J Neuroophthalmol 2017;37:56-64. [PMID: 28187082 DOI: 10.1097/WNO.0000000000000476] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Goldstein A, Rahman S. Seeking impact: Global perspectives on outcome measure selection for translational and clinical research for primary mitochondrial disorders. J Inherit Metab Dis 2021;44:343-57. [PMID: 33016339 DOI: 10.1002/jimd.12320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Chan F, Lax NZ, Davies CH, Turnbull DM, Cunningham MO. Neuronal oscillations: A physiological correlate for targeting mitochondrial dysfunction in neurodegenerative diseases? Neuropharmacology 2016;102:48-58. [DOI: 10.1016/j.neuropharm.2015.10.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
13 Peralta S, Torraco A, Iommarini L, Diaz F. Mitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies. Mitochondrion 2015;23:71-80. [PMID: 25638392 DOI: 10.1016/j.mito.2015.01.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
14 Lin J, Shen F, Lu J, Liang F, Zhang Y, Xie Z, Dong Y. WS635 Attenuates the Anesthesia/Surgery-Induced Cognitive Impairment in Mice. Front Aging Neurosci 2021;13:688587. [PMID: 34366827 DOI: 10.3389/fnagi.2021.688587] [Reference Citation Analysis]
15 Saada A. Mitochondria: mitochondrial OXPHOS (dys) function ex vivo--the use of primary fibroblasts. Int J Biochem Cell Biol 2014;48:60-5. [PMID: 24412346 DOI: 10.1016/j.biocel.2013.12.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
16 Procaccio V, Bris C, Chao de la Barca J, Oca F, Chevrollier A, Amati-bonneau P, Bonneau D, Reynier P. Perspectives of drug-based neuroprotection targeting mitochondria. Revue Neurologique 2014;170:390-400. [DOI: 10.1016/j.neurol.2014.03.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
17 Gammage PA, Viscomi C, Simard ML, Costa ASH, Gaude E, Powell CA, Van Haute L, McCann BJ, Rebelo-Guiomar P, Cerutti R, Zhang L, Rebar EJ, Zeviani M, Frezza C, Stewart JB, Minczuk M. Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo. Nat Med 2018;24:1691-5. [PMID: 30250142 DOI: 10.1038/s41591-018-0165-9] [Cited by in Crossref: 110] [Cited by in F6Publishing: 98] [Article Influence: 27.5] [Reference Citation Analysis]
18 Holzerová E, Prokisch H. Mitochondria: Much ado about nothing? How dangerous is reactive oxygen species production? Int J Biochem Cell Biol 2015;63:16-20. [PMID: 25666559 DOI: 10.1016/j.biocel.2015.01.021] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 7.6] [Reference Citation Analysis]
19 Emmanuele V, Ganesh J, Vladutiu G, Haas R, Kerr D, Saneto RP, Cohen BH, Van Hove J, Scaglia F, Hoppel C, Rosales XQ, Barca E, Buchsbaum R, Thompson JL, Dimauro S, Hirano M. Time to harmonize mitochondrial syndrome nomenclature and classification: A consensus from the North American Mitochondrial Disease Consortium (NAMDC). Molecular Genetics and Metabolism 2022. [DOI: 10.1016/j.ymgme.2022.05.001] [Reference Citation Analysis]
20 Arroyo JD, Jourdain AA, Calvo SE, Ballarano CA, Doench JG, Root DE, Mootha VK. A Genome-wide CRISPR Death Screen Identifies Genes Essential for Oxidative Phosphorylation. Cell Metab 2016;24:875-85. [PMID: 27667664 DOI: 10.1016/j.cmet.2016.08.017] [Cited by in Crossref: 133] [Cited by in F6Publishing: 115] [Article Influence: 22.2] [Reference Citation Analysis]
21 Nightingale H, Pfeffer G, Bargiela D, Horvath R, Chinnery PF. Emerging therapies for mitochondrial disorders. Brain 2016;139:1633-48. [PMID: 27190030 DOI: 10.1093/brain/aww081] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
22 Iannetti EF, Smeitink JAM, Willems PHGM, Beyrath J, Koopman WJH. Rescue from galactose-induced death of Leigh Syndrome patient cells by pyruvate and NAD.. Cell Death Dis 2018;9:1135. [PMID: 30429455 DOI: 10.1038/s41419-018-1179-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
23 Patrushev MV, Kamenski PA, Mazunin IO. Mutations in mitochondrial DNA and approaches for their correction. Biochemistry Moscow 2014;79:1151-60. [DOI: 10.1134/s0006297914110029] [Cited by in Crossref: 8] [Article Influence: 1.0] [Reference Citation Analysis]
24 Orssaud C, Bidot S, Lamirel C, Brémond Gignac D, Touitou V, Vignal C. [Raxone in the Leber optical neuropathy: Parisian experience]. J Fr Ophtalmol 2019;42:269-75. [PMID: 30712826 DOI: 10.1016/j.jfo.2018.06.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Šileikytė J, Forte M. The Mitochondrial Permeability Transition in Mitochondrial Disorders. Oxid Med Cell Longev 2019;2019:3403075. [PMID: 31191798 DOI: 10.1155/2019/3403075] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
26 Whitaker RM, Korrapati MC, Stallons LJ, Jesinkey SR, Arthur JM, Beeson CC, Zhong Z, Schnellmann RG. Urinary ATP Synthase Subunit β Is a Novel Biomarker of Renal Mitochondrial Dysfunction in Acute Kidney Injury. Toxicol Sci 2015;145:108-17. [PMID: 25666834 DOI: 10.1093/toxsci/kfv038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
27 Gioran A, Piazzesi A, Bertan F, Schroer J, Wischhof L, Nicotera P, Bano D. Multi-omics identify xanthine as a pro-survival metabolite for nematodes with mitochondrial dysfunction. EMBO J 2019;38:e99558. [PMID: 30796049 DOI: 10.15252/embj.201899558] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
28 Koene S, Dirks I, van Mierlo E, de Vries PR, Janssen AJWM, Smeitink JAM, Bergsma A, Essers H, Meijer K, de Groot IJM. Domains of Daily Physical Activity in Children with Mitochondrial Disease: A 3D Accelerometry Approach. JIMD Rep 2017;36:7-17. [PMID: 28092092 DOI: 10.1007/8904_2016_35] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
29 Leruez S, Amati-bonneau P, Verny C, Reynier P, Procaccio V, Bonneau D, Milea D. Mitochondrial dysfunction affecting visual pathways. Revue Neurologique 2014;170:344-54. [DOI: 10.1016/j.neurol.2014.03.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
30 Turnbull DM, Rustin P. Genetic and biochemical intricacy shapes mitochondrial cytopathies. Neurobiol Dis 2016;92:55-63. [PMID: 25684538 DOI: 10.1016/j.nbd.2015.02.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
31 Thompson Legault J, Strittmatter L, Tardif J, Sharma R, Tremblay-Vaillancourt V, Aubut C, Boucher G, Clish CB, Cyr D, Daneault C, Waters PJ, Vachon L, Morin C, Laprise C, Rioux JD, Mootha VK, Des Rosiers C; LSFC Consortium. A Metabolic Signature of Mitochondrial Dysfunction Revealed through a Monogenic Form of Leigh Syndrome. Cell Rep 2015;13:981-9. [PMID: 26565911 DOI: 10.1016/j.celrep.2015.09.054] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 10.1] [Reference Citation Analysis]
32 Rajendran J, Purhonen J, Tegelberg S, Smolander OP, Mörgelin M, Rozman J, Gailus-Durner V, Fuchs H, Hrabe de Angelis M, Auvinen P, Mervaala E, Jacobs HT, Szibor M, Fellman V, Kallijärvi J. Alternative oxidase-mediated respiration prevents lethal mitochondrial cardiomyopathy. EMBO Mol Med 2019;11:e9456. [PMID: 30530468 DOI: 10.15252/emmm.201809456] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
33 Barrow JJ, Balsa E, Verdeguer F, Tavares CD, Soustek MS, Hollingsworth LR 4th, Jedrychowski M, Vogel R, Paulo JA, Smeitink J, Gygi SP, Doench J, Root DE, Puigserver P. Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations. Mol Cell 2016;64:163-75. [PMID: 27666594 DOI: 10.1016/j.molcel.2016.08.023] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
34 Scarpelli M, Todeschini A, Volonghi I, Padovani A, Filosto M. Mitochondrial diseases: advances and issues. Appl Clin Genet 2017;10:21-6. [PMID: 28243136 DOI: 10.2147/TACG.S94267] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
35 Meyerson C, Van Stavern G, McClelland C. Leber hereditary optic neuropathy: current perspectives. Clin Ophthalmol 2015;9:1165-76. [PMID: 26170609 DOI: 10.2147/OPTH.S62021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 41] [Article Influence: 2.1] [Reference Citation Analysis]
36 Mootha VK, Chinnery PF. Oxygen in mitochondrial disease: can there be too much of a good thing? J Inherit Metab Dis 2018;41:761-3. [PMID: 29948481 DOI: 10.1007/s10545-018-0210-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
37 Byrnes J, Ganetzky R, Lightfoot R, Tzeng M, Nakamaru-Ogiso E, Seiler C, Falk MJ. Pharmacologic modeling of primary mitochondrial respiratory chain dysfunction in zebrafish. Neurochem Int 2018;117:23-34. [PMID: 28732770 DOI: 10.1016/j.neuint.2017.07.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
38 Karaa A, Haas R, Goldstein A, Vockley J, Cohen BH. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle 2020;11:909-18. [PMID: 32096613 DOI: 10.1002/jcsm.12559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
39 Burelle Y, Bemeur C, Rivard ME, Thompson Legault J, Boucher G, Morin C, Coderre L, Des Rosiers C; LSFC Consortium. Mitochondrial vulnerability and increased susceptibility to nutrient-induced cytotoxicity in fibroblasts from leigh syndrome French canadian patients. PLoS One 2015;10:e0120767. [PMID: 25835550 DOI: 10.1371/journal.pone.0120767] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
40 Koopman WJ, Beyrath J, Fung CW, Koene S, Rodenburg RJ, Willems PH, Smeitink JA. Mitochondrial disorders in children: toward development of small-molecule treatment strategies. EMBO Mol Med 2016;8:311-27. [PMID: 26951622 DOI: 10.15252/emmm.201506131] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 12.6] [Reference Citation Analysis]
41 Suomalainen A, Battersby BJ. Mitochondrial diseases: the contribution of organelle stress responses to pathology. Nat Rev Mol Cell Biol 2018;19:77-92. [DOI: 10.1038/nrm.2017.66] [Cited by in Crossref: 175] [Cited by in F6Publishing: 156] [Article Influence: 35.0] [Reference Citation Analysis]
42 Yu-Wai-Man P, Newman NJ. Inherited eye-related disorders due to mitochondrial dysfunction. Hum Mol Genet 2017;26:R12-20. [PMID: 28481993 DOI: 10.1093/hmg/ddx182] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
43 Swerdlow RH. Bioenergetic medicine. Br J Pharmacol 2014;171:1854-69. [PMID: 24004341 DOI: 10.1111/bph.12394] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
44 Gammage PA, Rorbach J, Vincent AI, Rebar EJ, Minczuk M. Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations. EMBO Mol Med 2014;6:458-66. [PMID: 24567072 DOI: 10.1002/emmm.201303672] [Cited by in Crossref: 159] [Cited by in F6Publishing: 138] [Article Influence: 19.9] [Reference Citation Analysis]
45 Yadak R, Sillevis Smitt P, van Gisbergen MW, van Til NP, de Coo IF. Mitochondrial Neurogastrointestinal Encephalomyopathy Caused by Thymidine Phosphorylase Enzyme Deficiency: From Pathogenesis to Emerging Therapeutic Options. Front Cell Neurosci 2017;11:31. [PMID: 28261062 DOI: 10.3389/fncel.2017.00031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
46 Yu-Wai-Man P, Votruba M, Burté F, La Morgia C, Barboni P, Carelli V. A neurodegenerative perspective on mitochondrial optic neuropathies. Acta Neuropathol 2016;132:789-806. [PMID: 27696015 DOI: 10.1007/s00401-016-1625-2] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 15.0] [Reference Citation Analysis]
47 Gwaltney C, Stokes J, Aiudi A, Mazar I, Ollis S, Love E, Espensen A, Shields AL. Development of a Patient-Reported Outcome Questionnaire to Evaluate Primary Mitochondrial Myopathy Symptoms: The Primary Mitochondrial Myopathy Symptom Assessment. J Clin Neuromuscul Dis 2020;22:65-76. [PMID: 33214391 DOI: 10.1097/CND.0000000000000303] [Reference Citation Analysis]
48 Finsterer J, Bindu PS. Therapeutic strategies for mitochondrial disorders. Pediatr Neurol 2015;52:302-13. [PMID: 25701186 DOI: 10.1016/j.pediatrneurol.2014.06.023] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
49 Wang H, Xu Z, Wu A, Dong Y, Zhang Y, Yue Y, Xie Z. 2-deoxy-D-glucose enhances anesthetic effects in mice. Anesth Analg 2015;120:312-9. [PMID: 25390277 DOI: 10.1213/ANE.0000000000000520] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
50 Viscomi C. Toward a therapy for mitochondrial disease. Biochem Soc Trans 2016;44:1483-90. [PMID: 27911730 DOI: 10.1042/BST20160085] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 4.4] [Reference Citation Analysis]
51 Morató L, Bertini E, Verrigni D, Ardissone A, Ruiz M, Ferrer I, Uziel G, Pujol A. Mitochondrial dysfunction in central nervous system white matter disorders: Mitochondrial Dysfunction in Brain White Matter. Glia 2014;62:1878-94. [DOI: 10.1002/glia.22670] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
52 Koene S, de Laat P, van Tienoven DH, Weijers G, Vriens D, Sweep FC, Timmermans J, Kapusta L, Janssen MC, Smeitink JA. Serum GDF15 Levels Correlate to Mitochondrial Disease Severity and Myocardial Strain, but Not to Disease Progression in Adult m.3243A>G Carriers. JIMD Rep. 2015;24:69-81. [PMID: 25967227 DOI: 10.1007/8904_2015_436] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
53 La Morgia C, Carbonelli M, Barboni P, Sadun AA, Carelli V. Medical management of hereditary optic neuropathies. Front Neurol 2014;5:141. [PMID: 25132831 DOI: 10.3389/fneur.2014.00141] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
54 Murayama K, Shimura M, Liu Z, Okazaki Y, Ohtake A. Recent topics: the diagnosis, molecular genesis, and treatment of mitochondrial diseases. J Hum Genet 2019;64:113-25. [PMID: 30459337 DOI: 10.1038/s10038-018-0528-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
55 Whitaker RM, Stallons LJ, Kneff JE, Alge JL, Harmon JL, Rahn JJ, Arthur JM, Beeson CC, Chan SL, Schnellmann RG. Urinary mitochondrial DNA is a biomarker of mitochondrial disruption and renal dysfunction in acute kidney injury. Kidney Int 2015;88:1336-44. [PMID: 26287315 DOI: 10.1038/ki.2015.240] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 7.7] [Reference Citation Analysis]
56 Carelli V, Chan DC. Mitochondrial DNA: impacting central and peripheral nervous systems. Neuron 2014;84:1126-42. [PMID: 25521375 DOI: 10.1016/j.neuron.2014.11.022] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 9.6] [Reference Citation Analysis]
57 Koene S, van Bon L, Bertini E, Jimenez-Moreno C, van der Giessen L, de Groot I, McFarland R, Parikh S, Rahman S, Wood M, Zeman J, Janssen A, Smeitink J. Outcome measures for children with mitochondrial disease: consensus recommendations for future studies from a Delphi-based international workshop. J Inherit Metab Dis 2018;41:1267-73. [PMID: 30027425 DOI: 10.1007/s10545-018-0229-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
58 Sofronova JK, Ilinsky YY, Orishchenko KE, Chupakhin EG, Lunev EA, Mazunin IO. Detection of Mutations in Mitochondrial DNA by Droplet Digital PCR. Biochemistry (Mosc) 2016;81:1031-7. [PMID: 27908228 DOI: 10.1134/S0006297916100011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
59 van der Lee R, Szklarczyk R, Smeitink J, Smeets HJ, Huynen MA, Vogel R. Transcriptome analysis of complex I-deficient patients reveals distinct expression programs for subunits and assembly factors of the oxidative phosphorylation system. BMC Genomics 2015;16:691. [PMID: 26369791 DOI: 10.1186/s12864-015-1883-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
60 Lorenz C, Lesimple P, Bukowiecki R, Zink A, Inak G, Mlody B, Singh M, Semtner M, Mah N, Auré K, Leong M, Zabiegalov O, Lyras EM, Pfiffer V, Fauler B, Eichhorst J, Wiesner B, Huebner N, Priller J, Mielke T, Meierhofer D, Izsvák Z, Meier JC, Bouillaud F, Adjaye J, Schuelke M, Wanker EE, Lombès A, Prigione A. Human iPSC-Derived Neural Progenitors Are an Effective Drug Discovery Model for Neurological mtDNA Disorders. Cell Stem Cell 2017;20:659-674.e9. [PMID: 28132834 DOI: 10.1016/j.stem.2016.12.013] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 14.8] [Reference Citation Analysis]
61 Rodenburg RJ. Mitochondrial complex I-linked disease. Biochimica et Biophysica Acta (BBA) - Bioenergetics 2016;1857:938-45. [DOI: 10.1016/j.bbabio.2016.02.012] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 14.8] [Reference Citation Analysis]
62 Hu SY, Zhuang QQ, Qiu Y, Zhu XF, Yan QF. Cell models and drug discovery for mitochondrial diseases. J Zhejiang Univ Sci B 2019;20:449-56. [PMID: 31090270 DOI: 10.1631/jzus.B1900196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
63 Akdoğan E, Tardu M, Garipler G, Baytek G, Kavakli İH, Dunn CD. Reduced Glucose Sensation Can Increase the Fitness of Saccharomyces cerevisiae Lacking Mitochondrial DNA. PLoS One 2016;11:e0146511. [PMID: 26751567 DOI: 10.1371/journal.pone.0146511] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
64 Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, Saneto R, Anselm I, Cohen BH, Falk MJ, Greene C, Gropman AL, Haas R, Hirano M, Morgan P, Sims K, Tarnopolsky M, Van Hove JL, Wolfe L, DiMauro S. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med 2015;17:689-701. [PMID: 25503498 DOI: 10.1038/gim.2014.177] [Cited by in Crossref: 226] [Cited by in F6Publishing: 169] [Article Influence: 28.3] [Reference Citation Analysis]
65 Yu-Wai-Man P, Votruba M, Moore AT, Chinnery PF. Treatment strategies for inherited optic neuropathies: past, present and future. Eye (Lond) 2014;28:521-37. [PMID: 24603424 DOI: 10.1038/eye.2014.37] [Cited by in Crossref: 84] [Cited by in F6Publishing: 69] [Article Influence: 10.5] [Reference Citation Analysis]
66 Koene S, Timmermans J, Weijers G, de Laat P, de Korte CL, Smeitink JA, Janssen MC, Kapusta L. Is 2D speckle tracking echocardiography useful for detecting and monitoring myocardial dysfunction in adult m.3243A>G carriers? - a retrospective pilot study. J Inherit Metab Dis 2017;40:247-59. [PMID: 28054208 DOI: 10.1007/s10545-016-0001-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
67 Tischner C, Wenz T. Keep the fire burning: Current avenues in the quest of treating mitochondrial disorders. Mitochondrion 2015;24:32-49. [DOI: 10.1016/j.mito.2015.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
68 Scarpelli M, Todeschini A, Rinaldi F, Rota S, Padovani A, Filosto M. Strategies for treating mitochondrial disorders: An update. Molecular Genetics and Metabolism 2014;113:253-60. [DOI: 10.1016/j.ymgme.2014.09.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
69 Zolkipli-Cunningham Z, Xiao R, Stoddart A, McCormick EM, Holberts A, Burrill N, McCormack S, Williams L, Wang X, Thompson JLP, Falk MJ. Mitochondrial disease patient motivations and barriers to participate in clinical trials. PLoS One 2018;13:e0197513. [PMID: 29771953 DOI: 10.1371/journal.pone.0197513] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
70 de Laat P, Rodenburg RR, Roeleveld N, Koene S, Smeitink JA, Janssen MC. Six-year prospective follow-up study in 151 carriers of the mitochondrial DNA 3243 A>G variant. J Med Genet 2021;58:48-55. [PMID: 32439810 DOI: 10.1136/jmedgenet-2019-106800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
71 Tur-Kaspa I, Jeelani R, Doraiswamy PM. Preimplantation genetic diagnosis for inherited neurological disorders. Nat Rev Neurol 2014;10:417-24. [PMID: 24866878 DOI: 10.1038/nrneurol.2014.84] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
72 Malty RH, Jessulat M, Jin K, Musso G, Vlasblom J, Phanse S, Zhang Z, Babu M. Mitochondrial targets for pharmacological intervention in human disease. J Proteome Res 2015;14:5-21. [PMID: 25367773 DOI: 10.1021/pr500813f] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
73 Yu-Wai-Man P, Soiferman D, Moore DG, Burté F, Saada A. Evaluating the therapeutic potential of idebenone and related quinone analogues in Leber hereditary optic neuropathy. Mitochondrion 2017;36:36-42. [PMID: 28093355 DOI: 10.1016/j.mito.2017.01.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
74 Inak G, Lorenz C, Lisowski P, Zink A, Mlody B, Prigione A. Concise Review: Induced Pluripotent Stem Cell-Based Drug Discovery for Mitochondrial Disease. Stem Cells 2017;35:1655-62. [PMID: 28544378 DOI: 10.1002/stem.2637] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
75 Murphy E, Ardehali H, Balaban RS, DiLisa F, Dorn GW 2nd, Kitsis RN, Otsu K, Ping P, Rizzuto R, Sack MN, Wallace D, Youle RJ; American Heart Association Council on Basic Cardiovascular Sciences, Council on Clinical Cardiology, and Council on Functional Genomics and Translational Biology. Mitochondrial Function, Biology, and Role in Disease: A Scientific Statement From the American Heart Association. Circ Res 2016;118:1960-91. [PMID: 27126807 DOI: 10.1161/RES.0000000000000104] [Cited by in Crossref: 179] [Cited by in F6Publishing: 112] [Article Influence: 29.8] [Reference Citation Analysis]
76 Yu-Wai-Man P. Genetic manipulation for inherited neurodegenerative diseases: myth or reality? Br J Ophthalmol 2016;100:1322-31. [PMID: 27002113 DOI: 10.1136/bjophthalmol-2015-308329] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
77 Enns GM. Advances in Mitochondrial Medicine. Journal of Inborn Errors of Metabolism and Screening 2018;6:232640981775296. [DOI: 10.1177/2326409817752961] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Maresca A, Del Dotto V, Romagnoli M, La Morgia C, Di Vito L, Capristo M, Valentino ML, Carelli V; ER-MITO Study Group. Expanding and validating the biomarkers for mitochondrial diseases. J Mol Med (Berl) 2020;98:1467-78. [PMID: 32851462 DOI: 10.1007/s00109-020-01967-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
79 Ibrahim I, Dominguez-valentin M, Segal B, Zeitouni A, da Silva SD. Mitochondrial mutations associated with hearing and balance disorders. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2018;810:39-44. [DOI: 10.1016/j.mrfmmm.2018.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
80 McCormack SE, Xiao R, Kilbaugh TJ, Karlsson M, Ganetzky RD, Cunningham ZZ, Goldstein A, Falk MJ, Damrauer SM. Hospitalizations for mitochondrial disease across the lifespan in the U.S. Mol Genet Metab 2017;121:119-26. [PMID: 28442181 DOI: 10.1016/j.ymgme.2017.04.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
81 Goldenberg AJ, Comeau AM, Grosse SD, Tanksley S, Prosser LA, Ojodu J, Botkin JR, Kemper AR, Green NS. Evaluating Harms in the Assessment of Net Benefit: A Framework for Newborn Screening Condition Review. Matern Child Health J 2016;20:693-700. [PMID: 26833040 DOI: 10.1007/s10995-015-1869-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
82 Walker MA, Miranda M, Allred A, Mootha VK. On the dynamic and even reversible nature of Leigh syndrome: Lessons from human imaging and mouse models. Curr Opin Neurobiol 2021;72:80-90. [PMID: 34656053 DOI: 10.1016/j.conb.2021.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Filograna R, Koolmeister C, Upadhyay M, Pajak A, Clemente P, Wibom R, Simard ML, Wredenberg A, Freyer C, Stewart JB, Larsson NG. Modulation of mtDNA copy number ameliorates the pathological consequences of a heteroplasmic mtDNA mutation in the mouse. Sci Adv 2019;5:eaav9824. [PMID: 30949583 DOI: 10.1126/sciadv.aav9824] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
84 Bianciardi L, Imperatore V, Fernandez-vizarra E, Lopomo A, Falabella M, Furini S, Galluzzi P, Grosso S, Zeviani M, Renieri A, Mari F, Frullanti E. Exome sequencing coupled with mRNA analysis identifies NDUFAF6 as a Leigh gene. Molecular Genetics and Metabolism 2016;119:214-22. [DOI: 10.1016/j.ymgme.2016.09.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
85 Farruggia P, Di Marco F, Dufour C. Pearson syndrome. Expert Rev Hematol 2018;11:239-46. [PMID: 29337599 DOI: 10.1080/17474086.2018.1426454] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
86 Meyer K, Buettner S, Ghezzi D, Zeviani M, Bano D, Nicotera P. Loss of apoptosis-inducing factor critically affects MIA40 function. Cell Death Dis 2015;6:e1814. [PMID: 26158520 DOI: 10.1038/cddis.2015.170] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 8.4] [Reference Citation Analysis]
87 Amorim R, Benfeito S, Teixeira J, Cagide F, Oliveira PJ, Borges F. Targeting Mitochondria: The Road to Mitochondriotropic Antioxidants and Beyond. In: Oliveira PJ, editor. Mitochondrial Biology and Experimental Therapeutics. Cham: Springer International Publishing; 2018. pp. 333-58. [DOI: 10.1007/978-3-319-73344-9_16] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
88 Schlieben LD, Prokisch H. The Dimensions of Primary Mitochondrial Disorders. Front Cell Dev Biol 2020;8:600079. [PMID: 33324649 DOI: 10.3389/fcell.2020.600079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
89 Koene S, Stolwijk NM, Ramakers R, de Vries M, de Boer L, Janssen MCH, de Groot I, Smeitink J. Quantification of gait in children with mitochondrial disease. J Inherit Metab Dis 2018;41:731-40. [PMID: 29532198 DOI: 10.1007/s10545-018-0148-5] [Reference Citation Analysis]
90 Camp KM, Krotoski D, Parisi MA, Gwinn KA, Cohen BH, Cox CS, Enns GM, Falk MJ, Goldstein AC, Gopal-Srivastava R, Gorman GS, Hersh SP, Hirano M, Hoffman FA, Karaa A, MacLeod EL, McFarland R, Mohan C, Mulberg AE, Odenkirchen JC, Parikh S, Rutherford PJ, Suggs-Anderson SK, Tang WH, Vockley J, Wolfe LA, Yannicelli S, Yeske PE, Coates PM. Nutritional interventions in primary mitochondrial disorders: Developing an evidence base. Mol Genet Metab 2016;119:187-206. [PMID: 27665271 DOI: 10.1016/j.ymgme.2016.09.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
91 de Haas R, Das D, Garanto A, Renkema HG, Greupink R, van den Broek P, Pertijs J, Collin RWJ, Willems P, Beyrath J, Heerschap A, Russel FG, Smeitink JA. Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease. Sci Rep 2017;7:11733. [PMID: 28916769 DOI: 10.1038/s41598-017-09417-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
92 Zhang J, Dong Y, Lining Huang, Xu X, Liang F, Soriano SG, Zhang Y, Xie Z. Interaction of Tau, IL-6 and mitochondria on synapse and cognition following sevoflurane anesthesia in young mice. Brain Behav Immun Health 2020;8:100133. [PMID: 34589883 DOI: 10.1016/j.bbih.2020.100133] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Muraresku CC, McCormick EM, Falk MJ. Mitochondrial Disease: Advances in clinical diagnosis, management, therapeutic development, and preventative strategies. Curr Genet Med Rep 2018;6:62-72. [PMID: 30393588 DOI: 10.1007/s40142-018-0138-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
94 Pitceathly RDS, Keshavan N, Rahman J, Rahman S. Moving towards clinical trials for mitochondrial diseases. J Inherit Metab Dis 2021;44:22-41. [PMID: 32618366 DOI: 10.1002/jimd.12281] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
95 Coppi L, Ligorio S, Mitro N, Caruso D, De Fabiani E, Crestani M. PGC1s and Beyond: Disentangling the Complex Regulation of Mitochondrial and Cellular Metabolism. Int J Mol Sci 2021;22:6913. [PMID: 34199142 DOI: 10.3390/ijms22136913] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Sundaramurthy S, SelvaKumar A, Ching J, Dharani V, Sarangapani S, Yu-Wai-Man P. Leber hereditary optic neuropathy-new insights and old challenges. Graefes Arch Clin Exp Ophthalmol 2021;259:2461-72. [PMID: 33185731 DOI: 10.1007/s00417-020-04993-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
97 Garone C, Minczuk M, Mascalchi M, Montomoli M, Guerrini R. Neuroimaging in mitochondrial disorders. Essays in Biochemistry 2018;62:409-21. [DOI: 10.1042/ebc20170109] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
98 Gerards M, Sallevelt SC, Smeets HJ. Leigh syndrome: Resolving the clinical and genetic heterogeneity paves the way for treatment options. Mol Genet Metab. 2016;117:300-312. [PMID: 26725255 DOI: 10.1016/j.ymgme.2015.12.004] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 8.4] [Reference Citation Analysis]
99 Vafai SB, Mootha VK. Medicine. A common pathway for a rare disease? Science 2013;342:1453-4. [PMID: 24357304 DOI: 10.1126/science.1248449] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
100 Lopez Sanchez M, Crowston J, Mackey D, Trounce I. Emerging Mitochondrial Therapeutic Targets in Optic Neuropathies. Pharmacology & Therapeutics 2016;165:132-52. [DOI: 10.1016/j.pharmthera.2016.06.004] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 6.5] [Reference Citation Analysis]
101 Avula S, Parikh S, Demarest S, Kurz J, Gropman A. Treatment of mitochondrial disorders. Curr Treat Options Neurol 2014;16:292. [PMID: 24700433 DOI: 10.1007/s11940-014-0292-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
102 Sperl W, Fleuren L, Freisinger P, Haack TB, Ribes A, Feichtinger RG, Rodenburg RJ, Zimmermann FA, Koch J, Rivera I, Prokisch H, Smeitink JA, Mayr JA. The spectrum of pyruvate oxidation defects in the diagnosis of mitochondrial disorders. J Inherit Metab Dis 2015;38:391-403. [PMID: 25526709 DOI: 10.1007/s10545-014-9787-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
103 Enns GM. Pediatric mitochondrial diseases and the heart. Curr Opin Pediatr 2017;29:541-51. [PMID: 28719387 DOI: 10.1097/MOP.0000000000000535] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
104 Varghese F, Atcheson E, Bridges HR, Hirst J. Characterization of clinically identified mutations in NDUFV1, the flavin-binding subunit of respiratory complex I, using a yeast model system. Hum Mol Genet 2015;24:6350-60. [PMID: 26345448 DOI: 10.1093/hmg/ddv344] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
105 Hirano M, Emmanuele V, Quinzii CM. Emerging therapies for mitochondrial diseases. Essays Biochem 2018;62:467-81. [PMID: 29980632 DOI: 10.1042/EBC20170114] [Cited by in Crossref: 59] [Cited by in F6Publishing: 25] [Article Influence: 14.8] [Reference Citation Analysis]
106 Friedrich VK, Rubel MA, Schurr TG. Mitochondrial genetic variation in human bioenergetics, adaptation, and adult disease. Am J Hum Biol 2021;:e23629. [PMID: 34146380 DOI: 10.1002/ajhb.23629] [Reference Citation Analysis]
107 Delhey LM, Nur Kilinc E, Yin L, Slattery JC, Tippett ML, Rose S, Bennuri SC, Kahler SG, Damle S, Legido A, Goldenthal MJ, Frye RE. The Effect of Mitochondrial Supplements on Mitochondrial Activity in Children with Autism Spectrum Disorder. J Clin Med 2017;6:E18. [PMID: 28208802 DOI: 10.3390/jcm6020018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]